OntoPharma
AI-Powered Drug Licensing Assistant
Streamlining regulatory compliance for pharmaceutical companies worldwide
Seed Funding Goal
$15 Million
Market Size 2025
$2 Billion
Projected 2040
$50 Billion
The Problem
-
Complex Regulatory Landscape
Pharmaceutical companies must navigate different regulatory requirements across 195+ countries, each with unique approval processes.
-
Time-Consuming Research
Teams spend months researching country-specific licensing requirements, often duplicating efforts across projects.
-
High Costs
Regulatory compliance teams are expensive, with large pharmaceuticals spending $15-50M annually on regulatory affairs.
-
Constantly Changing Regulations
Regulatory requirements frequently change, making it difficult to stay compliant across multiple markets.
The Bottom Line
Drug approval delays cost pharmaceutical companies an average of $2.2 million per day in lost sales – potentially billions over a product's lifecycle.
Our Solution
Introducing OntoPharma
Our AI-powered platform simplifies the complex drug approval process by generating customized licensing roadmaps for pharmaceutical products across global markets.
Input Drug Composition
Simply enter your drug's chemical composition and intended markets.
AI Processing
Our proprietary AI analyzes real-time regulatory data across 195+ countries.
Generate Custom Roadmap
Receive a step-by-step licensing pathway with required documentation, timelines, and fee estimates.
Real-Time Updates
Continuously monitor regulatory changes and receive alerts when they affect your products.
Key Benefits
Save Time
Reduce research time by 80%, cutting months of work to days.
Cut Costs
Reduce regulatory compliance costs by up to 60%.
Ensure Compliance
Minimize regulatory risks with up-to-date compliance requirements.
Accelerate Launch
Get drugs to market faster across multiple regions simultaneously.
Market Opportunity
Current Market
$2B
Drug Regulatory Tech Market Size (2025)
Projected Growth
$50B
Expected Market Size (2040)
GRC Market
$44B
Governance, Risk & Compliance (2029)
Market Growth Projection
2024
2025
2028
2030
2033
2036
2040
Market Drivers
Regulatory Complexity
Increasingly complex global regulatory requirements demand sophisticated compliance solutions.
Digital Transformation
Pharma companies accelerating digital adoption for regulatory processes following COVID-19.
AI Adoption
135% growth in AI implementation across pharmaceutical companies since 2020.
Global Expansion
Pharmaceutical companies aggressively expanding into emerging markets, requiring expertise in diverse regulatory environments.
The Opportunity
OntoPharma is positioned at the convergence of AI technology and regulatory compliance needs, targeting a rapidly growing market with a solution that delivers immediate ROI to pharmaceutical companies of all sizes.
Business Model
Revenue Streams
Software Subscription
- Tiered pricing model
- Annual contracts
- $1MK-$5M per year
Enterprise Solutions
- Custom integrations
- On-premise options
- $150M-$500M per year
API Access
- Usage-based pricing
- Partner integrations
- Per request or bulk rates
Target Customers
Big Pharma
Global pharmaceutical corporations with extensive portfolios
Mid-size Pharma
Companies with focused therapeutic areas seeking global expansion
Biotech Startups
Innovative companies bringing novel therapies to market
CROs & Consultancies
Service providers supporting drug development process
Financial Projections
15-Year Revenue Projection
Year 1
$20M
Year 2
$80M
Year 3
$150M
Year 4
$380M
Year 5
$490M
Key Financial Metrics
Competitive Advantage
| Features |
|
Traditional Consultants | Generic RegTech |
|---|---|---|---|
| Speed of Results |
Minutes
to Hours
|
Weeks to Months | Days to Weeks |
| Pharma-Specific AI | |||
| Global Market Coverage | 195+ Countries | Limited by Staff | Major Markets Only |
| Real-Time Updates | |||
| Cost |
Fixed
Subscription
|
High & Variable | Moderate |
| Drug Composition Analysis |
Our Unique Advantages
Proprietary AI Technology
Our specialized machine learning models have been trained on millions of regulatory documents and drug approval pathways specific to pharmaceutical products.
Molecular Analysis Engine
Our system can analyze drug compositions at the molecular level to identify potential regulatory concerns or special approval pathways in various jurisdictions.
Comprehensive Global Coverage
Unlike competitors who focus on major markets, our system provides detailed regulatory pathways for over 195 countries, including emerging markets with complex requirements.
Expert-Validated Content
Our system combines AI with oversight from regulatory experts with decades of experience at major regulatory bodies (FDA, EMA, NMPA, etc.), ensuring high accuracy.
Funding Request
Seed Round
$15,000,000
To accelerate product development and market entry
Fund Allocation
Detailed Breakdown
Product Development - $7.5M
AI model refinement/hosting, database expansion, UI/UX development, and comprehensive testing with regulatory agencies.
Team Expansion - $4.5M
Hiring key engineering talent, regulatory experts, support teams and data scientists to accelerate platform development.
Marketing & Sales - $2.75M
Building sales team, developing go-to-market strategy, and establishing industry partnerships.
Operations - $250K
Office space, legal, accounting, and administrative infrastructure to support growth.
Key Milestones
Q2 2025
Q2 2025
MVP Launch
Release initial version covering top 25 pharmaceutical markets with core functionality.
First 2 Paying Customers
Secure initial customers including at least 2 enterprise pharmaceutical companies.
Q3 2025
Q3 2025
First 2 Paying Customers
Secure initial customers including at least 2 enterprise pharmaceutical companies.
Q4 2026
Q4 2026
Global Coverage
Expand regulatory coverage to all 195+ countries and integrate real-time monitoring system.
Series A Preparation
$100M ARR, 10+ active customers, and platform enhancement for Series A funding.
Q1 2027
Q1 2027
Series A Preparation
$1M ARR, 30+ active customers, and platform enhancement for Series A funding.
Return on Investment
Path to Profitability
- Break-even within 12 months of launch
- 85% gross margins with recurring revenue model
- Customer acquisition cost recovered in under 6 months
- Projected $150M ARR by end of Year 3
Exit Strategy
- Primary: Strategic acquisition by pharma tech company or major pharmaceutical corporation (4-5 year horizon)
- Secondary: IPO potential with sufficient market penetration and revenue growth
- Target valuation of 8-10x revenue at acquisition
- Potential acquirers include Veeva Systems, IQVIA, and Oracle Health Sciences
Join Us in Revolutionizing Drug Licensing
Your $15M investment will help us transform pharmaceutical regulatory compliance worldwide
Our Team
Our team combines deep expertise in pharmaceutical regulatory affairs, artificial intelligence, and enterprise software development.
Matthew Hochstrasser
CoFounder & CEO
Key Investment Partner at Laissez-Faire Capital Partners
CFO at SQRBIT, INC
Jithendra Kumar R
CoFounder & CTO
Ex-Cisco AI Systems Research Engineer
MS(Research) at Ohio State University
Former CEO at Ontoborn
15+ years experience in AI/Software Engineering
Dr. Rajiv Ramnath
Chief Advisor
Former Director at National Science Foundation
Professor at The Ohio State Univeristy
Prithivraj Karunakaran
Ex-Saama, Subject Matter Expert
Expert in Pharma IT implementation
15+ years of expertise in Pharma Compliance
Planned Team Expansion
Technical Team
-
Senior ML Engineers (3)
Specializing in NLP and regulatory document processing
-
Full-Stack Developers (4)
Building intuitive interfaces and API integrations
-
MLOps Engineer
Building reliable, scalable infrastructure
Business & Domain Experts
-
VP of Sales & Business Development
With pharmaceutical industry connections
-
Regional Regulatory Experts (5)
Specialists in key markets (US, EU, Asia, LATAM, Middle East)
-
Customer Success Manager
Ensuring client adoption and satisfaction
Our Culture
We're building a team that combines pharmaceutical regulatory expertise with cutting-edge AI capabilities. Our culture emphasizes:
- Innovation-First Mindset
- Regulatory Excellence
- Customer-Centric Focus
- Global Perspective
Product Roadmap
Our strategic plan to develop, launch, and scale OntoPharma over the next 24 months
MVP Development
Key Deliverables
- Working MVP with drug composition analysis capabilities
- 5 beta testing partners from pharmaceutical industry
- Initial regulatory relationships with FDA and EMA
Key Deliverables
- Commercial launch with tiered subscription model
- First 10 paying customers including 2 enterprise clients
- Sales and marketing team in place
Market Launch
Key Deliverables
- Commercial launch with tiered subscription model
- First 10 paying customers including 2 enterprise clients
Scale & Expand
Key Deliverables
- Complete global regulatory database with real-time updates
- 30+ enterprise customers across biotech and pharma
- $10M+ monthly recurring revenue
Key Milestones
- Series A funding ($150M-$200M target)
- International office expansion
- Launch of companion products for regulatory documentation
Series A & Beyond
Key Milestones
- Series A funding ($150M-$200M target)
- International office expansion
Current Progress
AI Algorithm
75% Complete
Database
60% Complete
UI/UX
40% Complete
Ready for Next Steps
Our team has completed the foundational work and proof of concept. With your investment, we'll accelerate development, expand our team, and bring OntoPharma to market within 6 months.
Join Us in Revolutionizing Pharmaceutical Compliance
Your $15M seed investment will accelerate our mission to transform how pharmaceutical companies navigate the complex world of global drug licensing.
Strategic Investment
- Enter a $50B market growing rapidly
- High-margin SaaS recurring revenue model
- Projected 8-10x return within 4-5 years
Why Invest Now
- 75% of core AI technology already developed
- World-class team with 45+ years combined experience
- First-mover advantage in specialized AI-driven regulatory tech
Path to Success
- Market launch within 6 months
- Series A readiness in 18-24 months
- Clear path to acquisition by pharma tech giants
Next Steps
-
1
Schedule a Demo
See our current prototype in action with a live demonstration
-
2
Due Diligence
Review our technical documentation, financial projections, and team credentials
-
3
Investment Terms
Discuss investment structure, valuation, and board representation
Let's Transform Pharmaceutical Compliance Together
Join us on our mission to revolutionize how pharmaceutical companies navigate the complex world of global regulatory compliance.
Ready to Join Our Vision?
Reach out to discuss how your investment can help transform pharmaceutical compliance worldwide.
Chat on LinkedIn